Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Salivary Gland Cancer: early-phase trial registry
4 of 9 indexed Salivary Gland Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,916 of 28,707 conditions by registered trial count.
9 US clinical trials · 4 currently recruiting · #1,916 of 28,707 conditions by registered trial count
Salivary Gland Cancer: 9 US clinical trials tracked, 4 recruiting.
Salivary Gland Cancer is the subject of 9 registered US clinical trials on ClinicalTrials.gov, 4 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is Glenn J. Hanna, running 2 of these trials.
Enrollment posture brief
Registry condition salivary-gland-cancer
OPEN 4 | RECR 44% | LATE 0 | EARLY 9 | RANK #1916 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Acute Ischemic Stroke (44% recruiting · 27 trials)
Salivary Gland Cancer lists 4 open slots (44% of 9 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Salivary Gland Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Salivary Gland Cancer is recruiting below its size-band peers.
4 of 9 indexed trials (44.4%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Salivary Gland Cancer research.
Glenn J. Hanna accounts for 2 of 9 trials (22.2%). 8 distinct sponsors appear on at least one study for this condition label.
-
Most Salivary Gland Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 41 among the 9 trials that report a genuine target (sentinel values excluded). 8 of those (88.9%) plan for fewer than 100 participants.
-
Salivary Gland Cancer research is mostly interventional.
9 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
9 total, page 1 of 1
A Phase 2 Study of Zanidatamab in Patients With HER2-expressing Tumors
Jazz Pharmaceuticals
NCT06695845
Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Dana-Farber Cancer Institute
NCT04620187
A Phase 2 Trial of Ivonescimab for Patients With Advanced, Metastatic Salivary Gland Cancers
Glenn J. Hanna
NCT06805617
Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers
Brigham and Women's Hospital
NCT05553782
Lenvatinib and Pembrolizumab in People With Advanced Adenoid Cystic Carcinoma and Other Salivary Gland Cancers
Memorial Sloan Kettering Cancer Center
NCT04209660
Pembrolizumab With Chemotherapy for Poorly Chemo-responsive Thyroid and Salivary Gland Tumors
University of Chicago
NCT03360890
APG-115 in Salivary Gland Cancer Trial
University of Michigan Rogel Cancer Center
NCT03781986
9-ING-41 Plus Carboplatin in Salivary Gland Carcinoma
Glenn J. Hanna
NCT05010629
Amivantamab in Adenoid Cystic Carcinoma
Trisha Wise-Draper
NCT05074940
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 2 |
| Phase 2 | 7 |
Top Sponsors
Named interventions
Most-linked intervention names on Salivary Gland Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Salivary Gland Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Salivary Gland Cancer page
9 registered trials, 4 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 4 Salivary Gland Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Glenn J. Hanna sponsors the most Salivary Gland Cancer trials on record, review their full trial history before evaluating a specific study. See Glenn J. Hanna's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Salivary Gland Cancer condition card totals 9 registered trials; most-linked intervention Carboplatin; top US site state Massachusetts. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.